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Abstract
Introduction Recombinant human activated protein C (APC)
therapy has been shown to reduce short-term mortality in
patients with severe sepsis. However, survivors of sepsis may
have long-term complications affecting health-related quality of
life (HRQoL) and resource utilization. The objective of this study
was to evaluate prospectively the effect of APC on long-term
HRQoL and resource utilization compared with a
nonrandomized control group that received standard care.
Methods This was an observational cohort study at nine
Canadian intensive care units. Patients with severe sepsis who
survived to 28 days were recruited. Patients who received APC
formed the treatment group and those that did not formed the
standard care group. Patients who did not receive APC because
of central nervous system bleeding risk were excluded from the
standard care group. HRQoL (determined using the 36-item
Short Form) and resource use were recorded at 28 days, and 3,
5 and 7 months.
Results One hundred patients were enrolled (64 in the standard
care group and 36 in the APC group), with 70 patients
completing all follow-up visits. Over the 6 months of follow up,
APC-treated patients exhibited statistically significantly better
scores for the physical component score (P = 0.04) and trends
toward improvements in physical functioning (P = 0.12), role
physical (P = 0.10) and bodily pain (P = 0.14) as compared with
standard care patients. Shorter hospital length of stay was
observed for the APC group (36 days versus 48 days; P =
0.05).
Conclusion These findings challenge earlier assumptions
suggesting equivalent HRQoL and resource use in APC-treated
and standard care patients who survive severe sepsis.
Introduction
Each year approximately 750,000 patients in the USA develop
sepsis, and at least 215,000 of these cases are fatal [1]. Sev-
eral studies have documented that sepsis is associated with
increased hospital resource utilization and prolonged intensive
care unit (ICU) and hospital stay [2-5]. With such considerable
effects on associated morbidity and mortality, the economic
burden associated with sepsis has recently been estimated at
17 billion dollars each year in the USA alone [1]. As novel,
expensive therapies for the treatment of sepsis are introduced
into international markets, decision makers will need accurate
estimates of long-term outcomes and resource utilization if
they are to appreciate the relative merits and limitations of
these new therapies.
Morbidity associated with severe sepsis can have effects
beyond increases in resource consumption. Patients who sur-
vive sepsis often have severely compromised organ function
APC = activated protein C; HRQoL = health-related quality of life; ICU = intensive care unit; PCS = physical component score; PROWESS = Recom-
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that may result in persistent physical and psychological symp-
toms (dyspnoea, fatigue and depression), impaired functional
status (physical, social and emotional function) and reduced
health-related quality of life (HRQoL) [6].
In a large randomized clinical trial, recombinant human acti-
vated protein C (APC) therapy was shown to reduce 28-day
all-cause mortality in patients with severe sepsis from 30.8%
in the control group to 24.7% in the treatment group [7]. Long-
term follow-up analyses of this large trial have shown improved
survival for APC patients with Acute Physiology and Chronic
Health Evaluation II scores greater than 25 persisting at 2.5
years [8]. There have been a number of economic evaluations
of APC based on 28-day survival data [9-11]. Each has
assumed equivalent long-term quality of life and resource use
in surviving patients – an assumption that may or may not be
valid. Given that APC administration confers persistent long-
term effects on overall survival [12] and its proposed relation-
ship with inflammation, organ dysfunction and symptoms/func-
tional status [13], it could plausibly influence long-term
HRQoL. The previous literature has suggested that the degree
of organ dysfunction during ICU stay can have an impact on
HRQoL scores [14], lending support to the hypothesis that
APC may influence HRQoL through its effect on organ dys-
function recovery rates. A prospective evaluation of long-term
health outcomes and resource use associated with APC
would provide useful information and either support or chal-
lenge existing assumptions.
The primary objectives of this research were to assess
patient's quality of life at 28 days, and 3, 5 and 7 months after
treatment with APC, and to compare these data with those
from a similar cohort of patients who did not receive APC (we
have labelled this control population 'standard care'). The sec-
ondary objective was to assess differences in health resource
utilization between the two groups. Additionally, we evaluated
whether HRQoL following the sepsis episode returned to lev-
els of age-matched Canadians in the general population at 7
months (6 months follow up after day 28 after admission).
These data will allow us to assess better the value of novel
therapies such as APC to patients, clinicians and policy
makers.
Materials and methods
This study was conducted at nine ICUs at Canadian commu-
nity and teaching hospitals (see Acknowledgements, below,
for a complete list of sites and investigators) during the period
from February 2002 to January 2006 (enrolment period plus
follow-up phase).
Study population
Given that randomization of APC was not possible after publi-
cation of the Recombinant Human Activated Protein C World-
wide Evaluation in Severe Sepsis (PROWESS) study, our goal
was to develop a prospective cohort of patients who survived
an episode of severe sepsis and who were similar in all
respects except for the receipt, or not, of APC. All patients in
the ICU at participating sites were screened daily for the pres-
ence of severe sepsis using criteria similar to those used in the
PROWESS study (Additional file 1). We note that this proto-
col differed slightly in that it required two sepsis-induced
organ failures, rather than the one required in the PROWESS
study. When patients with sepsis were identified, daily data
collection was initiated. Decisions to prescribe APC, or not,
were at the discretion of the attending physicians based on
locally instituted guidelines and their clinical judgement; the
research protocol did not influence the use of APC in any
measurable way. Patients treated with APC formed the 'treat-
ment' arm and survivors were approached for enrolment in the
study.
All standard care (control group) patients had to meet the
'inclusion criteria' for severe sepsis similar to those estab-
lished by guidelines for enrolment in the large multicenter APC
trial [7], including diagnosis of sepsis with two or more organ
failures. However, if a septic patient did not receive APC, then
they could become a standard care patient if they survived
until day 28, at which time they could be approached for inclu-
sion in the study. We excluded from the standard care group
those patients who did not receive APC because of central
nervous system bleeding risks (history of severe head trauma
that required hospitalization, intracranial surgery, stroke within
the previous 3 months, or any history of intracerebral arteriov-
enous malformation, cerebral aneurysm, or central nervous
system mass lesion), because these patients probably have or
will have a poor HRQoL related to their underlying illness. This
exclusion ensured that bleeding risks were similar between
APC and standard care groups, because the bleeding risks
outlined above are exclusion criteria for APC patients.
Patient identification
Before ICU discharge or at day 28 from ICU admission (which-
ever came first), all surviving patients who met the eligibility cri-
teria for the observational study were identified and were
approached and asked for their consent to participate in this
long-term outcomes study. For patients who were unable to
give consent themselves, consent was sought from their sur-
rogate decision maker. Contact information for both the
patient and next of kin was obtained. To avoid an imbalance
between APC and standard care patients from each site, each
participating site enrolled in blocks of three APC and six stand-
ard care patients. Sites were not allowed to enrol more than
three APC or more than six standard care patients until both
blocks were full.
Study procedures
Upon enrolment, the research coordinator at each site gave
the enrolled patient (or surrogate) a package containing study
materials. Patients received copies of all data collection tools
used including the 36-item Short Form (SF-36) and a diary toAvailable online http://ccforum.com/content/11/6/R128
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keep track of health resource utilization. The research nurse at
each site then faxed the enrolment information to the Clinical
Evaluation Research Unit at the Kingston General Hospital.
From the date of ICU admission, at day 28, and at 3, 5 and 7
months from the date of ICU admission, personnel from the
Clinical Evaluation Research Unit contacted the patient or sur-
rogate by telephone. If at any point in the study patients or fam-
ilies lost their study materials, then a new package containing
study documents was mailed to them. If the patient was still in
hospital at any interval, the local research nurse completed
data collection forms with the patient. If the patient was too
sick or unable to participate in data collection, study personnel
contacted the next of kin requesting them to fill out data col-
lection forms. Surrogate assessments of SF-36 have been
shown to be reliable, particularly for assessments of physical
function [15].
If researchers were unable to contact the patient after four
attempts, or if the telephone number listed was not in service,
then the next of kin were contacted. If participants could not
be traced through next of kin, the 411 Directory Internet site
for each province was searched. Persons who could not be
traced through either of these methods were categorized as
'could not contact'.
Baseline data and hospital resource data were collected for
both APC and standard care patients. Data collection
included important baseline demographics (age, sex, Acute
Physiology and Chronic Health Evaluation II score, comorbid-
ity index [16], baseline organ failure and admission diagnosis),
process of care variables (concomitant medications, proce-
dures and so on) and outcomes (ICU mortality, length of stay,
duration of mechanical ventilation and hospital length of stay).
The functional comorbidity index was chosen rather than the
Charlson because of the latter's focus on long-term survival
and its inability to address HRQoL factors. The functional
comorbidity index was developed specifically to correlate with
long-term function, not survival.
36-Item Short Form
The SF-36 is a multipurpose survey of general health status
consisting of eight domains and 36 items. These domains and
items were selected from a battery of health status instruments
used in the Medical Outcomes Study to represent frequently
measured and affected aspects of quality of life [17]. All but
one of the 36 items are aggregated into eight subscales,
which can also be clustered to form two higher order scales:
the physical and mental health component scores. Each sub-
scale is scored from 0 to 100 (100 = optimal). A minimally clin-
ically important difference in the SF-36 is a 5-point difference
on the physical function domain or a 2-point difference on the
physical subscale [18]. The SF-36 is suitable for self-adminis-
tration or for administration by a trained interviewer in person
or by telephone. The SF-36 has been used in a variety of
patient populations, and normal values for age, sex and 14
chronic diseases have been published [18,19] for US popula-
tions, as well as more limited data for Canadian populations
[20]. Compared with other generic health status instruments,
the SF-36 has been shown to have better feasibility, internal
consistency, content validity and discriminative ability, and to
be more responsive to clinical improvement [21,22]. Recently,
Heyland and coworkers [6] demonstrated that the SF-36 has
good reliability and validity when used to measure HRQoL in
survivors of sepsis.
Resource utilization
To measure health care resource utilization, study patients
were given a diary upon discharge from hospital. Between
points of subject contact, the diary was used by the patients
to track health resource use. The health resource categories
included ICU length of stay, inpatient physiotherapy, emer-
gency visits, physician home visit, outpatient tests, family doc-
tor visit, specialist visit, other medical professional visit,
personal care, laundry service, housekeeping, meal prepara-
tion, transportation, shopping, respite care, adult day care,
occupational therapy, physiotherapy, home nursing, speech
language professional, social work, dietary assistance, meal
delivery and other services. In addition, the patients were
asked to document inability to work because of health reasons
and any restrictions in every day activities. At the point of fol-
low up, the interviewer phoned study participants and
obtained the information recorded in the diaries.
Sample size consideration
The primary objective was to detect a 10-point difference in
the physical functioning domain of the SF-36. In the context of
this study, we expected APC, a novel treatment that modulates
the underlying inflammatory disease process in sepsis, to
affect the physical outcomes more so than the mental, social,
or emotional domains. Although a 5-point difference in physi-
cal function is clinically important [18,23], a sample size large
enough to detect such a difference was not feasible (esti-
mated n = 634). Also, given that APC is a new therapeutic
agent associated with significant acquisition cost, a larger
treatment effect (10-point difference) was sought to justify its
use. Secondary outcomes included the remaining domains of
the SF-36 (role physical, bodily pain, general health, vitality,
social function, role emotional and mental health) and resource
utilization measures. A longitudinal as well as across treatment
comparison was undertaken in an attempt to detect any differ-
ences across or within groups over time.
We initially planned to enroll 70 patients who survived through
to day 28 and who received APC, and a cohort of approxi-
mately 140 standard care patients. We anticipated an attrition
rate of 20%, resulting in a final target sample size based of
approximately 56 APC patients and 112 patients in the stand-
ard care arm. We prospectively planned an unbalanced
recruitment ratio (1:2), given the anticipated smaller number ofCritical Care    Vol 11 No 6    Longo et al.
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APC patients as compared with potential standard care
patients.
A previous report showed that the physical functioning domain
had a standard deviation of 20.0 points [18]. With the same
magnitude of variation anticipated in our study, we anticipated
that this sample size would have sufficient power (>86%) to
detect a 10-point difference in the physical functioning domain
of the SF-36 at any visit, at an α level of 0.05 and based on a
two-tailed t-test. As a consequence of slow enrolment and
insufficient funding, we terminated enrolment after the first
100 patients.
Statistical methods
Each domain and the two summary component scales of the
SF-36 were modelled separately by a linear mixed effects
model for repeated measures. This model was estimated by
restricted maximum likelihood as implemented in PROC
MIXED of SAS (SAS Institute Inc., Cary, NC, USA) [24] and
used an unstructured covariance to account appropriately for
the repeated measures per subject. Age was added as a con-
tinuous covariate to adjust for age differences between treat-
ment groups. The primary analysis used all available
observations and treated HRQoL after death as missing. This
mixed model does not make the unrealistic assumption that
the missing data are similar to the nonmissing data, but rather
the less strict assumption that the missing values are similar to
nonmissing values for patients of the same age, treatment and
observed (pre-death) HRQoL. Thus, the model estimates the
expected HRQoL values for the average sample age and the
same HRQoL before death or loss to follow up. The robust-
ness of the results to this missing data assumption were
assessed by two sensitivity analyses representing two extreme
ways of handling deaths: setting all values after death to 0 and
including only patients who survived the entire duration of fol-
low up.
Significance values for the baseline demographics and other
outcomes were obtained using a Kruskal-Wallis test for con-
tinuous variables, the log-rank test for time to return to work,
Fisher's exact test for categorical variables with only two lev-
els, and the χ2 test for categorical variables with more than two
levels. We considered P values of 0.05 and below to be sig-
nificant, and values below 0.15 to be trending towards signifi-
cance. All analyses were performed using SAS 9.1 (SAS
Institute Inc.).
Ethics
Consent was obtained from participating patients and their
care givers before entry into the study. We obtained research
ethics board approval at each participating site.
Results
Study sample
A total of 164 patients were screened and satisfied the inclu-
sion criteria during the recruitment period; of these, 100
patients gave consent to participate in the follow-up study (36
receiving APC and 64 standard care patients). Among these
patients, one died and one could not be contacted during the
first month after treatment (Figure 1). These two patients were
excluded from all analysis, because no quality of life data were
captured past baseline. Baseline characteristics of the two
treatment groups for all patients are shown in Table 1. Patients
in treatment group (APC) were significantly younger (mean
age 54.7 years versus 62.6 years; P = 0.03). It was also noted
that the APC group tended to have had a greater proportion
of admissions from the emergency room (40% versus 27%),
and a lower proportion from the ward (20% versus 33%).
Baseline severity of illness, comorbidity indices and all other
patient characteristics were statistically similar. During the 6-
month follow-up period, patients in the treatment group (APC)
exhibited a trend toward a lower mortality rate compared with
those in the nontreatment (standard care) group (5.7% versus
17.5%; P = 0.13), although the difference was not statistically
significant, and because of limited sample size we did not con-
trol for age differences.
Heath-related quality of life
Averaged over the four follow-up assessments and adjusting
for age, patients in the APC-treated group had persistently
higher physical component score (P = 0.04) than did standard
care patients (Figure 2). In addition, the APC-treated group
had significantly higher role physical scores at months 3 and 5
(P = 0.01 and P = 0.05, respectively), although the difference
averaged over all four assessments did not reach statistical
significance (P = 0.10) because the groups were nearly iden-
tical at months 1 and 7 (Figure 3). There were also trends
favouring the APC group for the bodily pain (P = 0.14) and the
physical function (P = 0.12) domains (Figures 4 and 5). The
mental component scores and all other domains were similar
in the two groups (data not shown).
A sensitivity analysis setting all values after death to 0 provided
the following P  values:  P  = 0.02 for physical component
score, P = 0.57 for mental component score, P = 0.09 for
physical function, P = 0.05 for role physical, P = 0.07 for bod-
ily pain, P = 0.24 for general health, P = 0.38 for vitality, P =
0.36 for social functioning, P = 0.86 for role emotional and P
= 0.54 for mental health. A second sensitivity analysis exclud-
ing all patients who did not survive the entire 7 months (which
would exclude those lost to follow up) resulted in the following
P values: P = 0.04 for physical component score, P = 0.77 for
mental component score, for P = 0.12 physical function, P =
0.20 for role physical, P = 0.14 for bodily pain, P = 0.38 for
general health, P = 0.66 for vitality, P = 0.52 for social func-
tioning, P = 0.96 for role emotional and P = 0.93 for mental
health. As with our primary analysis, both sensitively analysesAvailable online http://ccforum.com/content/11/6/R128
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confirmed that physical component score was significantly
better in the APC group, whereas physical function, role phys-
ical and bodily pain exhibited a trend toward statistical signifi-
cance and none of the other domains suggested any
difference between groups.
Although patients in both the treatment (APC) and standard
care arm of this study showed significant improvement in all
domains from baseline (all P < 0.01) except general health, at
7 months after the episode of severe sepsis HRQoL was still
below that of age-matched controls for Canadians [19] (Fig-
ure 6).
Table 1
Demographics for all patients
Parameter APC (n = 35) Standard care (n = 63) Total (n = 98) P values
Age (years; mean ± SD) 54.7 ± 18.1 62.6 ± 15.3 59.8 ± 16.7 0.03
Sex 0.40
Female 19 (54.3%) 28 (44.4%) 47 (48.0%)
Male 16 (45.7%) 35 (55.6%) 51 (52.0%)
Admission type (n [%]) 0.92
Medical 3 (8.6%) 7 (11.1%) 10 (10.2%)
Surgical 19 (54.3%) 34 (54.0%) 53 (54.1%)
Missing 13 (38.0%) 22 (35.0%) 35 (36.0%)
ICU admission diagnosis (n [%]) 0.30
Cardiovascular/vascular 0 (0.0%) 3 (4.8%) 3 (3.1%)
Respiratory 7 (20.0%) 18 (28.6%) 25 (25.5%)
Gastrointestinal 7 (20.0%) 8 (12.7%) 15 (15.3%)
Neurological 2 (5.7%) 2 (3.2%) 4 (4.1%)
Sepsis 16 (45.7%) 16 (25.4%) 32 (32.7%)
Trauma 0 (0.0%) 4 (6.3%) 4 (4.1%)
Metabolic 0 (0.0%) 2 (3.2%) 2 (2.0%)
Vascular/cardiovascular 1 (2.9%) 2 (3.2%) 3 (3.1%)
Orthopaedic 1 (2.9%) 1 (1.6%) 2 (2.0%)
Missing 1 (3.0%) 7 (12.0%) 8 (9.0%)
Source of admission (n [%]) 0.08
ER 14 (40.0%) 17 (27.0%) 31 (31.6%)
OR elective 0 (0.0%) 5 (7.9%) 5 (5.1%)
OR emergency 7 (20.0%) 5 (7.9%) 12 (12.2%)
Other hospital 4 (11.4%) 10 (15.9%) 14 (14.3%)
Ward 7 (20.0%) 21 (33.3%) 28 (28.6%)
Missing 3 (8.6%) 5 (7.9%) 8 (8.2%)
Comorbidites (n [%]) 0.41
None 29 (82.9%) 51 (81.0%) 80 (81.6%)
One 6 (17.1%) 9 (14.3%) 15 (15.3%)
Two 0 (0.0%) 3 (4.8%) 3 (3.1%)
Functional comorbidity index (mean ± SD) 2.7 ± 2.9 2.1 ± 1.9 2.3 ± 2.3 0.74
APACHE II score (mean ± SD) 27.2 ± 7.5 26.3 ± 7.8 26.6 ± 7.7 0.48
APACHE II, Acute Physiology and Chronic Health Evaluation II; APC, activated protein C; ER, emergency room; ICU, intensive care unit; OR, 
operating room; SD, standard deviation.Critical Care    Vol 11 No 6    Longo et al.
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Resource utilization and return to work
Resource utilization was examined for all patients. Patients on
treatment (APC) had a shorter length of stay in hospital (36.0
days [interquartile range 21.0 to 58.0 days] versus 48.0 days
[interquartile range 31.0 to 78.4 days]; P = 0.05). There were
no other significant differences for any of the other health serv-
ices (Table 2).
Of enrolled patients, 21% were employed before their ICU ill-
ness. There was no difference in the number of patients who
returned to work overall. Comparing the employment status of
the two groups, only a small amount of them (21.4%) were
employed before hospitalization. No difference was detected
between the two groups in employment status at each time
point.
The time to return to employment was compared between
groups for the 21 patients who were employed before hospi-
talization. After 1 month, nine out of 10 (90%) patients in the
APC group returned to work, as compared with seven out of
11 (64%) patients in the standard care group. By 7 months all
of the patients in the APC group returned to work, as
compared with eight out of 11 (73%) patients in the standard
care group. Although this is a small sample size, there was a
trend suggesting that the APC group returned to work faster
(P = 0.096).
Figure 1
Patient flow diagram for study participants Patient flow diagram for study participants. APC, activated protein C; CNC, could not contact; SF-36, 36-item Short Form.Available online http://ccforum.com/content/11/6/R128
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Discussion
HRQoL may be an important indicator of overall recovery from
a serious illness. This is the first report to compare long-term
HRQoL between patients treated with APC and those receiv-
ing standard care. Our results suggest that patients treated
with APC have improved health outcomes and appear physi-
cally to recover more quickly, as compared with those who do
not receive APC treatment. Our results apear to be robust
under a variety of analysis assumptions.
These findings appear plausible because it is likely that a drug
focused on improving the pathophysiology of sepsis will have
a continuum of effect on patients, potentially anchored at one
end by improvements at a cellular level, but presumably then
acting to improve individual organ or multiorgan function, and
hopefully leading to a reduction in death rate. It is similarly
likely, even in the absence of a survival benefit between groups
treated with APC or not, that via beneficial actions at the cel-
Figure 2
SF-36 physical component scores during the follow-up period (age- adjusted) SF-36 physical component scores during the follow-up period (age-
adjusted). APC, activated protein C; PCS, physical component score; 
SF-36, 36-item Short Form.
Figure 3
SF-36 role physical scores during the follow-up period (age-adjusted) SF-36 role physical scores during the follow-up period (age-adjusted). 
APC, activated protein C; SF-36, 36-item Short Form.
Figure 4
SF-36 bodily pain scores during the follow-up period (age-adjusted) SF-36 bodily pain scores during the follow-up period (age-adjusted). 
APC, activated protein C; SF-36, 36-item Short Form.
Figure 5
SF-36 physical function scores during follow-up period (age-adjusted) SF-36 physical function scores during follow-up period (age-adjusted). 
APC, activated protein C; SF-36, 36-item Short Form.Critical Care    Vol 11 No 6    Longo et al.
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lular or organ level APC might lead to more subtle improve-
ments in organ function and recovery that could translate into
positive effects on HRQL among those patients who did sur-
vive, even without a difference in rate of survival.
These data may challenge the underlying assumption that
HRQoL is similar for all survivors in the long term, regardless
of treatment regimen. We note that most of the reported eco-
nomic models employ similar utility scores for APC treated and
standard care survivors. Yet other literature suggests a strong
correlation between SF-36 scores and utility scores in general
populations [25], diabetes [26] and cardiovascular disease
[27]. If this holds true in a septic population, then existing
literature should be viewed as a conservative estimate of qual-
ity-adjusted survival benefit for patients treated with APC.
Increased utility scores and reduced resource use may trans-
late into a more favourable incremental cost-effectiveness ratio
than has been reported [11-13]. This study has also demon-
strated that patients with severe sepsis improve significantly in
the 7 months after admission. However, patients surviving
severe sepsis, similar to those surviving acute respiratory dis-
tress syndrome [28], do not attain equivalent measures of
health as compared with age-matched Canadian control indi-
viduals [20].
Weycker and coworkers [29] demonstrated that hospitaliza-
tions account for the majority of the total medical care costs.
Our data on resource use suggest that, at least for the initial
hospitalization, patients treated with APC stayed in hospital for
shorter periods of time and therefore were less likely to require
hospital resources. Although short-term resource use data
have been published [30] and demonstrated that older
patients treated with APC have statistically significant reduc-
tions in ICU days, hospital days, ventilator-free days, and vaso-
pressor-free days, this is the first paper to report on longer
term resource use in patients with severe sepsis treated with
APC. Although our study did not capture costing data on each
of these services, it would be expected that the additional cost
of APC would be partially offset by reductions in hospital
length of stay.
Our study has limitations that should be noted. Although the
intent was to recruit 210 patients, because of limited
resources and difficulty in enrolling patients, we were able to
enrol only 100 patients during the planned recruitment period.
Despite this, there was a statistically significant difference for
the physical composite score of the SF-36. A larger sample
size might have resulted in a statistically significant finding on
those domains exhibiting a trend toward significance. A more
comprehensive examination of baseline values, including time
to first organ failure, bleeding risk and organ dysfunction,
might have allowed us to assess better whether notable differ-
ences between groups existed. Hence, the absence of these
measures is a possible source of variability between groups.
As with any nonrandomized, observational study, bias is pos-
sible so that differences between groups may be due to fac-
tors other than the presence or absence of treatment. To
understand such biases, we captured important baseline
demographics (such as age, comorbid illness and underlying
severity of illness, among others). The groups appeared to be
similar for all measured demographics and disease character-
istics except age and source of admission. Age was controlled
for in the analysis, but no adjustment was made for source of
admission. Although there may be an influence related to
source of admission, there is limited literature on its impact on
HRQoL. Iapichino and colleagues [31] has shown that ward
admissions do increase the chances of mortality (but no effect
from emergency admissions), which may correlate with
HRQoL scores, but otherwise the impact that source of admis-
sion has on HRQoL is unknown. Additionally, we were only
able to enrol a portion of all eligible patients (61%). The demo-
graphic details on those patients who were screened but
elected not to participate were not captured. Also, because
there were only a limited number of APC patients available, it
is possible that some selection bias could have occurred. To
minimize bias sites were instructed to take all consecutive
treated patients up to the ratio of 3:6. If they filled there quota
of consecutive controls without having enough treated, then
they passed on further enrolments to the control group. Enrol-
ment was therefore consecutive with the exception of the
control group, so if a selection bias between groups exists it is
probably minimal. We recognize that the aforementioned
issues related to source of admission and selection bias may
create differences between the two groups even after adjust-
ing for age. Because it is possible that these differences could
account for some of the observed differences in HRQoL seen
between groups, these results should be viewed as
suggestive only, and therefore they should be interpreted with
caution.
In the case of patients who we were unable to contact at fol-
low-up visits, we employed a standard procedure to contact
Figure 6
SF-36 scores for sepsis patients 7 months after admission versus  Canadian age-adjusted norms SF-36 scores for sepsis patients 7 months after admission versus 
Canadian age-adjusted norms. BP, bodily pain; Cdn, Canadian; GH, 
General Health; MCS, mental component score; MH, mental health; 
PCS, physical component score; PF, physical function; RE, role emo-
tional; RP, role physical; SF, social functioning; SF-36, 36-item Short 
Form.Available online http://ccforum.com/content/11/6/R128
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them. We did not use vital statistics for those patients who we
were unsuccessful in contacting. In this regard, we might have
overstated the survival statistics, although this would be true
for both arms of the study. Also, the fact that an analysis
excluding those lost to follow up provided similar results sug-
gested that the differences in loss to follow up between
groups had a limited impact on the observed results.
Finally, the generalizability of our observational study reflects
that of the patients with severe sepsis at high risk for death, as
defined in our protocol. Many patients with severe sepsis may
fall outside the eligibility criteria used in the present study, and
hence the changes in HRQoL or resource use may be different
from our results in the severe sepsis populations not included
in this research.
Because this is a small cohort design it may be presumptive in
assuming that these populations are identical even after
adjusting for age differences. Conversely, it is also inappropri-
ate to assume that the differences in outcomes are purely the
result of population differences. A more neutral position, and
one that these authors have taken, is that these results are
suggestive and warrant further research that will either sup-
port or refute these preliminary findings.
Conclusion
Overall quality of life among patients with severe sepsis
showed good recovery in the 7 months after disease diagno-
sis, but patients did not attain full health, which is consistent
with follow up of other forms of critical illness [6]. Patients
treated with APC overall appeared to do at least as well or
better in HRQoL measurements than those not treated (stand-
ard care), and had lower resource use for hospital services.
The inferences drawn from these observations admittedly
could be challenged given the limitations of a nonrandomized,
observational study, and they suggest that further prospective
evaluations are warranted. The significance of the findings of
this study is that they challenge previous assumptions of
equivalence between APC-treated and standard care patients
regarding postsepsis quality of life and utility scores. If our
results prove to be valid, then the incremental cost-effective-
ness ratio of APC may be more favourable than reported in
recent publications [11-13]. These findings provide prelimi-
nary results that may aid clinicians and decision makers in
determining the value of APC and will also be helpful in
designing evaluations of future therapies in the management
of sepsis. Future phase III follow-up studies should measure
HRQoL and utilities for at least up to 6 months after randomi-
zation, ideally incorporating the use of propensity scores to
improve the matching between the two groups.
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